GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » Operating Income

BioVaxys Technology (BioVaxys Technology) Operating Income : $-2.36 Mil (TTM As of Jul. 2023)


View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Operating Income?

BioVaxys Technology's Operating Income for the three months ended in Jul. 2023 was $-0.43 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jul. 2023 was $-2.36 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. BioVaxys Technology's Operating Income for the three months ended in Jul. 2023 was $-0.43 Mil. BioVaxys Technology's Revenue for the three months ended in Jul. 2023 was $0.00 Mil. Therefore, BioVaxys Technology's Operating Margin % for the quarter that ended in Jul. 2023 was %.

BioVaxys Technology's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BioVaxys Technology's annualized ROC % for the quarter that ended in Jul. 2023 was -232.88%. BioVaxys Technology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2023 was %.


BioVaxys Technology Operating Income Historical Data

The historical data trend for BioVaxys Technology's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Operating Income Chart

BioVaxys Technology Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22
Operating Income
- -0.17 -0.83 -5.18 -2.98

BioVaxys Technology Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.70 -0.68 -0.68 -0.58 -0.43

BioVaxys Technology Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jul. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioVaxys Technology  (OTCPK:BVAXF) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BioVaxys Technology's annualized ROC % for the quarter that ended in Jul. 2023 is calculated as:

ROC % (Q: Jul. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Apr. 2023 ) + Invested Capital (Q: Jul. 2023 ))/ count )
=-1.7 * ( 1 - 0% )/( (1.102 + 0.358)/ 2 )
=-1.7/0.73
=-232.88 %

where

Note: The Operating Income data used here is four times the quarterly (Jul. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

BioVaxys Technology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Jul. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Apr. 2023  Q: Jul. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.7/( ( (0 + max(-0.647, 0)) + (0 + max(-1.027, 0)) )/ 2 )
=-1.7/( ( 0 + 0 )/ 2 )
=-1.7/0
= %

where Working Capital is:

Working Capital(Q: Apr. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.655) - (1.302 + 0 + 0)
=-0.647

Working Capital(Q: Jul. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.515) - (1.542 + 0 + 0)
=-1.027

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jul. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

BioVaxys Technology's Operating Margin % for the quarter that ended in Jul. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Jul. 2023 )/Revenue (Q: Jul. 2023 )
=-0.425/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


BioVaxys Technology Operating Income Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


BioVaxys Technology (BioVaxys Technology) Business Description

Traded in Other Exchanges
Address
146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4
BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.